PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
about
Targeting CDK6 in cancer: State of the art and new insightsNew directions for drug-resistant breast cancer: the CDK4/6 inhibitorsTherapeutic targeting of replicative immortalityCIViC databaseRecent advances of highly selective CDK4/6 inhibitors in breast cancerCDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell CarcinomaThe history and future of targeting cyclin-dependent kinases in cancer therapy.Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomasComprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic TargetsGenomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negativeProgress with palbociclib in breast cancer: latest evidence and clinical considerations.Cell cycle proteins as promising targets in cancer therapyThe Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors.A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.Cell-Cycle Therapeutics Come of Age.Twenty-gene-based prognostic model predicts lung adenocarcinoma survival.
P2860
Q26796499-7FB58469-146B-4376-8905-FE0768712454Q26797396-6C982311-3CF2-4403-844B-B7B2D2D20694Q27027457-1DDC14A3-0202-4953-889B-B78D064D9483Q27612411-DF8245B8-79C9-40C2-8049-F56BD369794FQ33602076-DE01CF3C-57A9-4332-802F-04DB0FCB9B50Q33614544-AB1F2DF4-5954-4624-AFBA-0D543E4A2167Q33947929-CA2F6A92-13D9-44FB-A749-603D296630FAQ34460347-461BA2B1-01D7-481A-AAC2-ABB129869F14Q35653135-FAF014F3-9A0D-473F-849A-97AF2DF361AAQ35869498-456B75A3-F3E6-4481-8505-8615E2D6FD81Q36304907-0110C334-F083-44E2-B1C4-563ABB0A2E67Q36562082-9A00A09F-5661-4C32-8295-55F29303D7F9Q37028708-9B4C1F1D-2A18-4E11-9042-7C640FA047C5Q37269251-3D5BAB5D-EEF5-4230-80F1-97309E4DDAB5Q37632170-DA46C0FF-09F3-4A88-BC86-1ED6B0322AF7Q37693690-8E4F45FA-7EFA-40DC-96E6-9687C6973D32Q39183079-57067D33-E093-4456-BDF6-0DC766431752Q40331337-15D27CFE-2C02-48B8-BF51-B13EE5082533Q41194460-06FF10C8-54EE-4AE2-8E06-8CCE79F192A8Q47129923-17713C9F-369F-438C-BD4B-9F0FB2E5D177Q47239499-2AE483C9-E8EB-4FF9-83F5-9035C3154E0FQ47271244-0FF68A97-EBA9-4211-A495-A7AE938201A2Q50959563-A828EBD8-4A4B-4034-9B20-EE5B09120CC0Q55280668-EA2772A3-B282-4781-A19A-D7268097E778
P2860
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@ast
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@en
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@nl
type
label
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@ast
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@en
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@nl
prefLabel
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@ast
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@en
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@nl
P2093
P1433
P1476
PD-0332991, a potent and selec ...... rkers predict for sensitivity.
@en
P2093
Amrita J Desai
Arie S Belldegrun
Dennis J Slamon
Eileen Taschereau
Erika VON Euw
Fairooz F Kabbinavar
Habib Hamidi
Hsiao-Wang Chen
James G Christensen
Joshua E Logan
P304
P407
P577
2013-08-01T00:00:00Z